Who can participate?
Children and teens 10 to 17 years old who have been diagnosed with Crohn’s Disease and are taking either Infliximab (Remicade) or Adalimumab (Humira) may be eligible to participate.
What will happen in the study?
This study involves 3 study visits in a week. Here are some of the things that will happen in this study:
You and your child will come in at 8 am for a full-day visit (8 hours), after he/she fasts from the night before.
Your child will:
- Have an IV placed in his/her arm to collect blood
- Receive vitamin D in capsule
- Be able to eat a provided breakfast 30 minutes after taking the vitamin D
- Have two additional blood draws during this visit from the same IV. You may opt to not have an IV in place.
You will bring your child in for a blood draw 24 hours after completing the first visit, and then 7 days later. These two additional visits will be brief. The only restrictions are that your child should not take any vitamin D supplements or use a tanning bed during this 7-day period.
You will be given a consent form that thoroughly explains all of the details of the study. A member of the study staff will review the consent form with you and will be sure that all of your questions are answered.